# Ireland Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Ireland HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Ireland (IRL)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $31.2B
- Products: 33
- Buyer markets: 26
- Average CAGR: +13.9%
- Global sector size: $532.3B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $255.4B | $18.5B | $76.6B | +14.0% | 15 | +6.1% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $67.9B | $6.4B | $21.9B | +51.0% | 10 | +7.4% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $16.3B | $17.3M | $16.7B | +0.3% | 3 | +0.2% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $14.9B | $2.8B | $15.6B | +33.7% | 5 | +8.4% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $21.8B | $586.4M | $15.0B | +22.3% | 7 | +3.8% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $26.0B | $1.6B | $13.7B | +6.4% | 8 | +2.6% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.1B | $527.7M | $13.7B | -0.2% | 2 | +7.5% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $20.9B | $324.0M | $11.3B | +5.6% | 4 | +1.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $10.5B | $3.2M | $8.5B | +6.7% | 3 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $41.1M | $5.8B | +11.4% | 2 | +0.4% |
| HS 290110 - Acyclic hydrocarbons: saturated | $2.9B | $3.0K | $5.1B | -3.4% | 2 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $6.4B | $137.9M | $5.0B | +28.9% | 3 | +2.0% |
| HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $6.8B | $122.6K | $5.0B | +41.7% | 2 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $2.8B | $8.7M | $4.6B | +30.7% | 2 | +0.4% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $5.7M | $4.1B | +12.6% | 2 | +0.1% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $10.8B | $327.1M | $3.8B | +27.7% | 2 | +3.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $3.6B | $1.3M | $3.4B | -19.5% | 2 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $181.9K | $3.3B | -18.1% | 2 | +0.0% |
| HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $862.9 | $2.4B | -10.5% | 1 | +0.0% |
| HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $295.3K | $2.4B | +36.0% | 1 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $999.9 | $2.1B | -15.1% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $40.4M | $1.9B | +10.0% | 1 | +1.1% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $1.2K | $1.9B | -0.3% | 1 | +0.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $2.2B | $657.3 | $1.8B | -29.3% | 1 | +0.0% |
| HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $53.3 | $1.8B | -58.1% | 1 | +0.0% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $69.5 | $1.8B | -4.1% | 1 | +0.0% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $1.7B | $2.2K | $1.7B | -15.2% | 1 | +0.0% |
| HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $101.3 | $1.7B | -34.3% | 1 | +0.0% |
| HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $107.3K | $1.7B | -3.0% | 1 | +0.0% |
| HS 293219 - Heterocyclic compounds: with oxygen hetero-atom(s) only, containing an unfused furan ring (whether or not hydrogenated) in the structure, n.e.c. in item no. 2932.1 | $990.6M | $88.8 | $1.5B | +11.6% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $682.4K | $1.4B | +14.8% | 1 | +0.1% |
| HS 293722 - Steroidal hormones, their derivatives and structural analogues: halogenated derivatives of corticosteroidal hormones | $1.5B | $24.8K | $1.3B | -3.3% | 1 | +0.0% |
| HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $450.4 | $1.2B | -23.5% | 1 | +0.0% |

## Best markets

- Slovenia (SVN): $38.6B calculated opportunity across 6 products.
- Switzerland, Liechtenstein (CHE): $32.6B calculated opportunity across 3 products.
- USA, Puerto Rico and US Virgin Islands (USA): $30.9B calculated opportunity across 12 products.
- China (CHN): $28.1B calculated opportunity across 11 products.
- Italy (ITA): $17.5B calculated opportunity across 4 products.
- Germany (DEU): $17.2B calculated opportunity across 7 products.
- Belgium (BEL): $14.0B calculated opportunity across 4 products.
- France (FRA): $7.6B calculated opportunity across 5 products.
- Canada (CAN): $7.6B calculated opportunity across 4 products.
- United Kingdom (GBR): $7.5B calculated opportunity across 4 products.
- Spain (ESP): $7.4B calculated opportunity across 3 products.
- Netherlands (NLD): $6.8B calculated opportunity across 2 products.

## Growth stars

- HS 300215: +51.0% average CAGR, $21.9B calculated opportunity.
- HS 310420: +41.7% average CAGR, $5.0B calculated opportunity.
- HS 285390: +36.0% average CAGR, $2.4B calculated opportunity.
- HS 293719: +33.7% average CAGR, $15.6B calculated opportunity.
- HS 293590: +30.7% average CAGR, $4.6B calculated opportunity.
- HS 300220: +28.9% average CAGR, $5.0B calculated opportunity.
- HS 382200: +27.7% average CAGR, $3.8B calculated opportunity.
- HS 382499: +22.3% average CAGR, $15.0B calculated opportunity.
- HS 340220: +14.8% average CAGR, $1.4B calculated opportunity.
- HS 300490: +14.0% average CAGR, $76.6B calculated opportunity.

## Diversification opportunities

- HS 300490: 15 buyer markets, $76.6B calculated opportunity.
- HS 300215: 10 buyer markets, $21.9B calculated opportunity.
- HS 300439: 8 buyer markets, $13.7B calculated opportunity.
- HS 382499: 7 buyer markets, $15.0B calculated opportunity.
- HS 293719: 5 buyer markets, $15.6B calculated opportunity.
- HS 300212: 4 buyer markets, $11.3B calculated opportunity.
- HS 293399: 3 buyer markets, $16.7B calculated opportunity.
- HS 382600: 3 buyer markets, $8.5B calculated opportunity.
- HS 300220: 3 buyer markets, $5.0B calculated opportunity.
- HS 293359: 2 buyer markets, $13.7B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.